Cover Image

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to trans...

Full description

Saved in:
Bibliographic Details
Main Authors: Michallet, Mauricette (Author) , Dreger, Peter (Author) , Sobh, Mohamad (Author) , Koster, Linda (Author) , Hoek, Jennifer (Author) , Boumendil, Ariane (Author) , Scheid, Christof (Author) , Fox, Christopher P. (Author) , Wulf, Gerald (Author) , Krüger, William (Author) , Gelder, Michel van (Author) , Corradini, Paolo (Author) , Russo, Domenico (Author) , Passweg, Jakob (Author) , Schoemans, Hélène (Author) , Bethge, Wolfgang (Author) , Schaap, Nicolaas (Author) , Cornelissen, Jan (Author) , Browne, Paul (Author) , Durakovic, Nadira (Author) , Muller, Lutz (Author) , Montoto, Silvia (Author) , Kroger, Nicolaus (Author) , Schetelig, Johannes (Author)
Format: Article (Journal)
Language:English
Published: [2020]
In: Bone marrow transplantation
Year: 2019, Volume: 55, Issue: 5, Pages: 884-890
ISSN:1476-5365
DOI:10.1038/s41409-019-0742-7
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-019-0742-7
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-019-0742-7
Get full text
Author Notes:Mauricette Michallet, Peter Dreger, Mohamad Sobh, Linda Koster, Jennifer Hoek, Ariane Boumendil, Christof Scheid, Christopher P. Fox, Gerald Wulf, William Krüger, Michel van Gelder, Paolo Corradini, Domenico Russo, Jakob Passweg, Hélène Schoemans, Wolfgang Bethge, Nicolaas Schaap, Jan Cornelissen, Paul Browne, Nadira Durakovic, Lutz Muller, Silvia Montoto, Nicolaus Kroger, Johannes Schetelig, on behalf of the French Cooperative Group for CLL, SFGM-TC, and the EBMT ChronicMalignancy and Lymphoma Working Parties
Description
Summary:The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.
Item Description:Published online: 7 November 2019
Gesehen am 29.09.2020
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-019-0742-7

Similar Items